Adage Capital Management, L.P., along with managing members Robert Atchinson and Phillip Gross, filed an amended Schedule 13G with the SEC on November 12, 2026, disclosing beneficial ownership of Common Shares of Helus Pharma Inc. as of September 30, 2026.

Key Highlights

  • Total beneficial ownership: Each reporting person beneficially owns 5,479,250 Common Shares of Helus Pharma Inc., representing 7.48% of the class.
  • Warrant component: The reported position includes 229,250 Common Shares issuable upon exercise of warrants directly held by Adage Capital Partners, L.P.
  • Shared voting and dispositive power: All 5,479,250 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Shares outstanding basis: The 7.48% figure is calculated based on 73,060,172 Common Shares outstanding as of September 1, 2026, as reported in the company's Registration Statement on Form S-8 filed September 1, 2026, and assumes exercise of the warrants held by ACP.
  • Issuer formerly known as: The filing identifies Helus Pharma Inc. as formerly known as Cybin Inc., a corporation incorporated under the laws of the Province of Ontario, Canada.
  • Reporting persons: The three reporting persons are Adage Capital Management, L.P. (investment manager), Robert Atchinson, and Phillip Gross, all with a business address at 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

Adage Capital's Amended 13G Position in Helus Pharma as of September 30, 2026

According to the filing, Adage Capital Management, L.P. ("ACM") serves as the investment manager of Adage Capital Partners, L.P. ("ACP"), which directly holds the Common Shares and warrants being reported. The filing states that ACM is a Delaware limited partnership, and that Robert Atchinson and Phillip Gross each serve as managing members of Adage Capital Partners, L.L.C., the general partner of ACM, as well as managing members of other affiliated entities in the Adage Capital organizational structure. The three reporting persons are collectively filing this amended Schedule 13G with respect to their shared indirect beneficial ownership.

The aggregate beneficial ownership reported is 5,479,250 Common Shares, which includes 229,250 Common Shares issuable upon exercise of warrants, according to the filing. All voting and dispositive power over the reported shares is shared among the reporting persons, with no sole voting or dispositive power reported by any of them. The percentage of class, 7.48%, is calculated against 73,060,172 Common Shares outstanding as of September 1, 2026, as the filing states, and assumes exercise of the warrants held by ACP.

The filing notes that Helus Pharma Inc. is formerly known as Cybin Inc. and is incorporated under the laws of the Province of Ontario, Canada, with principal executive offices at 100 King Street West, Suite 5600, Toronto, Ontario, Canada M5X 1C9. The filing also states that it "should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein," and that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross filed an amended Schedule 13G disclosing aggregate beneficial ownership of 5,479,250 Common Shares, or 7.48%, of Helus Pharma Inc. (formerly Cybin Inc.), including 229,250 shares underlying warrants, as of September 30, 2026.